BIO-GENE TECHNOLOGY LTD — AGM Information 2022

E N A B L I N G T H E N E X T G E N E R A T I O N O F N O V E L I N S E C T I C I D E S

==> picture [385 x 540] intentionally omitted <==

BIO-GENE TECHNOLOGY LIMITED

==> picture [261 x 269] intentionally omitted <==

1 8 N O V E M B E R 2 0 2 2 Annual General Meeting P R E S E N T E D B Y Robert Klupacs N O N - E X E C U T I V E C H A I R M A N Richard Jagger

C E O

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company’s announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitution a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. no representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

2

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

OUR STRATEGIC OBJECTIVE

==> picture [299 x 319] intentionally omitted <==

Generate multiple revenue streams from technology licensing fees, milestone payments and royalties by

Securing & owning active ingredient product registrations

==> picture [42 x 42] intentionally omitted <==

Working with strong commercial partners on product development; marketing and distribution

Developing proprietary manufacturing and production know-how

Potential partnership agreements across multiple geographies and different end-use markets, with collaboration programs now underway in two of our target segments

3

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

IMPORTANT POSITIVE PROGRESS OVER THE PAST 12 MONTHS

Significant improvements for Qcide and Flavocide production

Completion of Clarke commercial Agreement Additional MTAs signed with global companies to undertake preliminary analysis of our products Share Placement completed Appointment of Head of Regulatory Affairs Strategic placement to new shareholder Positive results for Stage 3 of the stored grain program

Registration review process with commercial partners and biochemical classification submission to US EPA Patent allowances granted in the U.S. (April), with further Additional efficacy data applications in other major (Purdue ) to support new patent applications commercial markets

Initiation of Plant Breeder’s rights program for Qcide International audit of toll manufacturers for Flavocide

==> picture [960 x 135] intentionally omitted <==

----- Start of picture text -----

Nov 2021 to Nov2022
4
----- End of picture text -----

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

PUBLIC HEALTH: COMMERCIAL AGREEMENT SIGNED ON CLARKE MOSQUITO PROJECT

Clarke is the largest vertically integrated company in public health mosquito control

Market Opportunity

Results of Phase 2 Testing

Very positive results indicate the suitability of Bio-Gene products as mosquito control technology

Commercial Development Agreement Signed

Development of novel formulations

Next Steps

Clarke undertaking Phase 3 trials (somewhat weather dependent) using new formulations

Initial Field of Use: US$100m[1]

Global market $650m[1]

Target formulations identified for progression to Phase 3 field trials Confidence for both companies to move forward with commercial negotiations as per the Option agreement

Phase 3 field testing

Agreement is for the U.S. market

Cost of studies borne by Clarke, with shared report of results

Field studies designed to confirm suitability of laboratory developed formulations for field use & EPA registration

==> picture [44 x 45] intentionally omitted <==

5

1 Global Mosquito Control Market, Research Report 2020, Forecast to 2026

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

CONSUMER PRODUCTS: EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT

Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand

Market Opportunity

Initial Field of Use

Fly & mosquito electric evaporator Ant bait gel and ant spray

ROFR to negotiate additional applications within consumer market

Initial Territory

E.U., U.K., A/NZ

ROFR to negotiate additional territories within consumer market

Revenue Model

Up-front licence fee

Milestone payments prior to registration

On-going royalties on end-use product sales

Development costs borne by Evergreen

Initial Field of Use: US$600m[1]

Total European consumer insecticide market: US$2b[1]

==> picture [152 x 86] intentionally omitted <==

6

1. Research and Markets report, December 2019: Europe Household Insecticides Market to 2027 - Regional Analysis and Forecasts By Insect Type; Composition; Packaging; Distribution Channel .

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

CROP PROTECTION: UPDATE ON STORED GRAIN PROJECT

Grains Research and Development Corporation (GRDC) Department of Agriculture and Fisheries - Queensland (DAF)

Results of Phase 3 testing

Further Discussions

Data show the ability for Flavocide, when used in combination (at low rates) to control the full range of stored grain pests over 9 months for susceptible strains and 3-9 months for resistant strains (commercially acceptable time frame).

Bio-Gene is discussing next steps with potential partners to progress the commercial development of Flavocide as a stored grain protectant

Next we will discuss support from the GRDC

==> picture [106 x 55] intentionally omitted <==

==> picture [139 x 58] intentionally omitted <==

Field testing completed Nov/Dec 2021

Final reporting on these results March 2022

Positive outcome allows us to move forward

Market opportunity in Australia is relatively small, but there is significant global potential (A$1b)[1]

7

1 Market and markets report – grain protectants global market forecast to 2023

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

IMPORTANT PROGRESS - COMMERCIAL

Other commercial discussions

Additional MTAs

Efficacy testing

• Recent visit to Europe

• Meetings with existing and new companies for product evaluation & commercial discussions

• Valuable to have the opportunity to conduct face to face meetings and develop relationships.

• Opportunities exist for further commercial development over the coming months as well as new relationships into 2023

• On-going process of adding new companies under MTAs to undertake formal testing program. Additional MTAs signed after recent Europe visit

• Studies performed by these companies ultimately give Bio-Gene additional options for going to market

• Additional studies underway for specific evaluation of technology

• Animal Health

• Consumer

• Crop Protection

• Public Health

• Extension work to identify additional key targets and applications to support our commercial discussions and further develop our I.P. portfolio

Continuing to develop our commercial relationships will ultimately provide further market access & revenue opportunities for Bio-Gene

8

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

IMPORTANT PROGRESS ACROSS OTHER KEY AREAS

Patents

• Patent allowance in the United States

• 1 additional recently submitted in Australia (Qcide)

• Applications under review in other key markets

• Other data collated for new submissions

Other I.P. Developments

• Recent research completed has the potential to identify new I.P. (patent) for the company

• Work on Qcide tree phenotypes has enabled commencement of Plant Breeders Rights program

• I.P. can be in the form of patents, technical

Review Of Registration Requirements

• Completed a regulatory review analysis with global consultants to look at the specific data requirements for USA, European Union and Australia across our different market segments

• Clear understanding developed relating to read-across potential for different applications and regulatory jurisdictions.

• Contact with regulatory agencies in key target jurisdictions with our commercial partners

• Submission made with EPA in the United States for a Biochemical classification of Flavocide.

Manufacturing

• Flavocide manufacturing validation – scale-up process has confirmed ability to produce larger quantities - 100Kg then 1,000kg

• Projects to further improve the economics of production of Flavocide are continuing

• Last Qcide harvest confirmed production improvements based on modified temperature & pressure

• Commercial plant tissue culture service provider has been initiated to establish the superior tree lines

• & manufacturing knowhow, trade secrets

On-going research is focused on developing data to support key commercial discussions as well as enhancing our I.P. portfolio

9

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

KEY PRIORITIES FOR THE NEXT 12 MONTHS

==> picture [895 x 276] intentionally omitted <==

----- Start of picture text -----

Progressing
Broadening our future
development work
opportunities via new Building our data to
associated with
partnerships support efficacy, novel
existing partnerships
update Mode of Action, and
strengthen our IP
Optimising our
Advancing our
manufacturing and
regulatory data and
production processes,
progress with
scaling up production
governing bodies
Advancing the terms
of our partnerships
----- End of picture text -----

2 0 2 2 A N N U A L G E N E R A L M E E T I N G

A CLEAR ROAD MAP FOR GENERATING VALUE – MEDIUM TERM

==> picture [778 x 332] intentionally omitted <==

----- Start of picture text -----

2024-2026
– MEDIUM TERM
2022-2024
•
2021-2022 First regulatory
• Additional approval and
2020-2021 commercial sales
application testing -
internal and with • Additional
2018-2020 •
Manufacturing scale- partners registration
up of Flavocide & • submissions
Converting
•
Efficacy data in Qcide additional MTAs into • Potential new
multiple settings • Building regulatory collaborative product
•
• Advancing safety data package development development
Proof of principle
and tox testing • agreements program
efficacy testing Securing initial
• • Confirming novel agreements with (commercial) • Commercial
Preliminary safety data
Mode of Action commercial partners • Applying for formal production of
• Product formulation
claims (Evergreen & Clarke) recognition of novel Flavocide & Qcide
concepts Mode of Action
• •
Development Creating additional
•
Testing with 3 [rd] parties •
agreements and IP (patents technical Completing data
additional MTAs know-how) package for final
submission
----- End of picture text -----

• Securing additional IP

POTENTIAL UPFRONT AND MILESTONE PAYMENTS, LICENSING FEES

AND ROYALTIES

11

E N A B L I N G T H E N E X T G E N E R A T I O N O F N O V E L I N S E C T I C I D E S

==> picture [385 x 539] intentionally omitted <==

BIO-GENE TECHNOLOGY LIMITED 1 8 N O V E M B E R 2 0 2 2 Annual General Meeting

==> picture [261 x 269] intentionally omitted <==

T H A N K Y O U